Navigation Links
Additional Data From Satraplatin SPARC Phase 3 Trial Presented at,European Association of Urology Congress

plied by such forward-looking statements. Actual results could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward-looking statements contained in this press release. In particular, there can be no guarantee that additional information relating to the safety, efficacy or tolerability of satraplatin may be discovered upon further analysis of data from the SPARC trial or analysis of additional data from other ongoing clinical trials for satraplatin. Furthermore, we cannot guarantee that satraplatin will be approved for marketing in a timely manner, if at all, by regulatory authorities nor that, if marketed, satraplatin will be a successful commercial product. We direct you to GPC Biotech's Annual Report on Form 20-F for the fiscal year ended December 31, 2005, Pharmion's Annual Report on Form 10-K for the fiscal year ended December 31, 2006 and other reports filed with the U.S. Securities and Exchange Commission for additional details on the important factors that may affect the future results, performance and achievements of either GPC Biotech or Pharmion. Forward-looking statements speak only as of the date on which they are made and neither GPC Biotech nor Pharmion undertakes any obligation to update these forward-looking statements, even if new information becomes available in the future.

The scientific information discussed in this press release related to satraplatin is investigative. Satraplatin has not yet been approved by the FDA in the U.S., the EMEA in Europe or any other regulatory authority and no conclusions can or should be drawn regarding its safety or effectiveness. Only the relevant regulatory authorities can determine whether satraplatin is safe and effective for the use(s) being investigated.

CONTACT: Breanna Burkart, or Anna Sussman, Directors, Investor Relationsand Corporate Communications, both of Pharmion Corporation,+1-720-564-9150; or Martin Braendle, Director,
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
3. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
6. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
7. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
8. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
11. Additional Efficacy Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at Annual Meeting of American Urological Association
Post Your Comments:
(Date:7/31/2015)...  In today,s ever-changing marketplace, call centers must meet ... connected, and increasingly impatient with slow service. The need ... and tools is driving call centers to explore new ... According to research by benchmarking firm, Best Practices, LLC, ... a call center study realize the impact of social ...
(Date:7/31/2015)... RnRMarketResearch.com adds Syringes and ... that provides an overview of syringes and needles ... in-house databases, secondary and primary research. ... pipeline spread across 124 pages, talking about 13 ... 5 figures is now available at http://www.rnrmarketresearch.com/syringes-and-needles-pipeline-review-2015-market-report.html ...
(Date:7/31/2015)... , July 31, 2015  Xcelience, a ... that it has made a structured cash investment ... company specializing in milling, micronization and powder size ... help grow Powdersize,s business while simultaneously adding a ... Xcelience,s portfolio of capabilities. "As ...
Breaking Medicine Technology:Best Practices in Building World-Class Consumer & Over-the-Counter Call Centers 2Syringes and Needles Market Products Pipeline Review 2015 Report 2Syringes and Needles Market Products Pipeline Review 2015 Report 3Syringes and Needles Market Products Pipeline Review 2015 Report 4Syringes and Needles Market Products Pipeline Review 2015 Report 5Xcelience Makes Structured Cash Investment in Powdersize 2Xcelience Makes Structured Cash Investment in Powdersize 3
... June 21 Thomson Reuters announced today that it has ... change the way biotechnology, pharmaceutical and academic organizations find partnering opportunities ... , ... organizations with drugs in development. It enables authorized users to share ...
... , June 18 /PRNewswire-Asia-FirstCall/ -- Tongjitang Chinese,Medicines Company ... leading,specialty pharmaceutical company focusing on the development, manufacturing,marketing and selling ... its financial results for the quarter ended March 31, ... the Quarter Ended March 31, 2010, -- ...
Cached Medicine Technology:Thomson Reuters Creates The Outpartnering Registry, a Free Resource to Improve Drug Development Partnering 2Thomson Reuters Creates The Outpartnering Registry, a Free Resource to Improve Drug Development Partnering 3Tongjitang Chinese Medicines Company Reports First Quarter 2010 Financial Results 2Tongjitang Chinese Medicines Company Reports First Quarter 2010 Financial Results 3Tongjitang Chinese Medicines Company Reports First Quarter 2010 Financial Results 4Tongjitang Chinese Medicines Company Reports First Quarter 2010 Financial Results 5Tongjitang Chinese Medicines Company Reports First Quarter 2010 Financial Results 6Tongjitang Chinese Medicines Company Reports First Quarter 2010 Financial Results 7Tongjitang Chinese Medicines Company Reports First Quarter 2010 Financial Results 8Tongjitang Chinese Medicines Company Reports First Quarter 2010 Financial Results 9Tongjitang Chinese Medicines Company Reports First Quarter 2010 Financial Results 10Tongjitang Chinese Medicines Company Reports First Quarter 2010 Financial Results 11Tongjitang Chinese Medicines Company Reports First Quarter 2010 Financial Results 12Tongjitang Chinese Medicines Company Reports First Quarter 2010 Financial Results 13Tongjitang Chinese Medicines Company Reports First Quarter 2010 Financial Results 14Tongjitang Chinese Medicines Company Reports First Quarter 2010 Financial Results 15
(Date:8/1/2015)... Winamac, In (PRWEB) , ... August 02, 2015 , ... ... this month which will help the continuity of care for patients at this natural ... afraid of the unknown," Clinic Director Mary Heal said. "Heather's role is vital to ...
(Date:8/1/2015)... TX (PRWEB) , ... August 01, 2015 , ... The ... concern among both men and women often causing pain and discomfort. Those who spend ... this circulatory problem, and Northeast Houston Vein Center is doing what it can to ...
(Date:8/1/2015)... ... August 01, 2015 , ... ... (“GPP”) portfolio company has acquired Premier Physical Therapy & Wellness (“Premier”) — with ... of state-of-the-art clinics. , “Our acquisition of Premier Physical Therapy & Wellness solidifies ...
(Date:8/1/2015)... ... ... “ reTXT ” was featured on NewsWatch as part of its monthly AppWatch, ... iOS, Android, and Windows. Joe Toohey, the host of AppWatch and technology expert, conducted ... any message including ones already sent. , While text messaging has more features than ...
(Date:7/31/2015)... ... 2015 , ... When the weather turned hot and warm-season turfgrasses, such as ... called Leisure Time(TM) zoysia . It's nicknamed LTZ(TM) for short. Incidentally, both names ... new type of sod, Super-Sod is giving away red Adirondack chairs with the Leisure ...
Breaking Medicine News(10 mins):Health News:New Patient Advocate Enhances Natural Health Care 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2
... increase in the incidence of malignant tumors, lymphomas ... of aspartame appears // to link the artificial ... a study accepted for publication today by the ... of the study, the first to demonstrate multipotential ...
... slowing the progression of Alzheimer’s’ disease. The study was ... // . ,The research team assessed the degree ... 342 patients attending a memory clinic. They then monitored ... The average age of the patients was 73. Most ...
... cases in China and Indonesia, the World Health Organization (WHO) ... with the H5N1 // avian influenza virus that has resulted ... birds. ,More than half the people infected – ... the announcement from Beijing officials November 16 that its Centre ...
... destination was the highlight of presentations made at the ... for Tourism Renuka Chowdhury, who // inaugurated the India ... only is India known for its hospitality, but also ... know how to do the best"., ,Chowdhury released ...
... used in a leading private hospital in New Delhi. ... technology. This will pave way for further 'bloodless' surgeries. ... its new KTP laser, surgery would become a bloodless ... Earlier, patients had to stay at least five days ...
... the use of Actemra in the treatment of rheumatoid ... treatment modality that uses disease modifying anti-rheumatic drugs (DMARDs ... found to provide symptomatic relief and improve sensation of ... disease in which the lining of the joints becomes ...
Cached Medicine News:Health News:Artificial Sweetners Not Really Safe?, 2Health News:Novel Actemra monotherapy in treating patients with early aggressive rheumatoid arthritis 2
Superior Skin Care...FlexWear skin barrier provides skin protection for an extended wear time....
Protects skin from corrosive drainage with the standard wear, FlexWear skin barrier. Convenient: accommodates stomas up to 102 mm; wide bottom opening permits hand access; attached pouch closure....
FlexWear is a cross-linked hydrocolloid skin barrier that provides aggressive adherence and is designed for more than one day weartime....
Inquire...
Medicine Products: